AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 3 - (NewsRx.com & NewsRx.net) -- Acambis (ACAM) announced the start of a phase I trial of its investigational vaccine against West Nile virus, ChimeriVax-West Nile.
Since it was first identified in New York in 1999, the West Nile virus has swept through 45 U.S. states, causing disease in more than 12,000 people and resulting in the deaths of several hundred individuals. In 2003 alone, it has affected more than 8,200 people and caused 182 deaths. The virus has also spread south to Central America and the Caribbean, and north into Canada where it has been identified in seven provinces.
Acambis used its proprietary ChimeriVax technology to develop the investigational ChimeriVax-West Nile vaccine and has conducted a series of successful pre-clinical studies on the vaccine. Acambis has now started a phase I clinical trial in humans.
The trial is being conducted in Lenexa, Kansas under a U.S. Food and Drug Administration Investigational New Drug application. The trial is a randomized, double-blind out-patient study in 60 healthy adult volunteers. It will test the safety, tolerability and immunogenicity of the ChimeriVax-West Nile ...
Source: HighBeam Research, First human trial of West Nile vaccine to begin.